Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women
Authors:
- 1 September 2000
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 119 (3) , 631-638
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized TrialJournal of Bone and Mineral Research, 2000
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritisGastroenterology, 1999
- Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronateCurrent Therapeutic Research, 1999
- Alendronate gastric ulcersAlimentary Pharmacology & Therapeutics, 1999
- Osteoporosis: Review of the Evidence for Prevention, Diagnosis and Treatment and Cost-Effective AnalysisOsteoporosis International, 1998
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 1998
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseasesCurrent Therapeutic Research, 1996
- Pamidronate: An unrecognized problem in gastrointestinal tolerabilityOsteoporosis International, 1994
- Rolling review: upper gastrointestinal bleedingAlimentary Pharmacology & Therapeutics, 1993